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Over sixty years ago, nerve growth factor (NGF) was originally discovered as a 
neurotrophic factor essential for the survival of sensory and sympathetic neurons during 
development. However, recent studies in patients with chronic pain indicate elevated 
levels of NGF in their sera and within injured and inflamed tissues. Abnormal 
neurotrophin action has been suggested to have an effect on acute and chronic pain, and 
in the development of degenerative diseases such as Alzheimer’s, neuropathy, and 
cancer. NGF signals through two different types of receptors: TrkA and p75. These 
signals can be disrupted by the presence of small molecules inhibitors such as PD90780, 
ALE-0450, and PQC 083 by specifically binding to NGF. The binding by these 
molecules antagonizes the action of NGF from binding to its receptors, therefore blocking 
its signalling pathways. This could have a potential application in pain control and 
treatment of degenerative diseases. More recently, pain therapy has focused on selective 
NGF inhibition. 
The aim of this study was to utilize gene expression analysis to investigate the intricate 
results of signalling in NGF treated cells compared to cells treated with both NGF and NGF 
inhibitors. A better understanding of genetic networks may contribute to the identification 
of novel drug targets, and more sensitive diagnostic strategies.  
In this research, peak time expression for Egr-1 in NGF treated cells was evaluated. Also, 
Egr-1 gene expression was assessed in NGF treated cells using semi-quantitative RT-PCR. 
This may provide a better way to identify new drugs through the examination of cell 
signalling response. Moreover, these findings will be helpful as a model for in vivo 
applications. 
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Chapter 1  
INTRODUCTION 
This chapter outlines pain definitions and mechanisms. The discovery of NGF, its structure, 
receptors, signalling pathway and role in chronic pain and inflammation will also be 
discussed. Moreover, therapeutic trials that targeted NGF receptors or signalling pathways, 
as an alternative method of pain management, will be presented. NGF inhibitory 
compounds and their mechanisms in NGF inhibition will be discussed and finally, different 
gene expression techniques will be outlined.  
In this study, the main focus is to evaluate the capability of reported small molecule 
inhibitors to inhibit NGF signalling pathways in a PC12 cell line. It is a critical step 
towards the ultimate goal of finding a cure for chronic pain. Results of this research can 
determine the effectiveness of specific small molecule inhibitors and pursue further 
research in vivo models prior to introduction to clinical trials.  
1.1 Pain 
Understanding the mechanism of pain is crucial because it improves safe and efficient 
pain treatment and also it is a critical step in decreasing medical complications. Although 
no one has escaped the experience of pain, pain determination and management was 
ignored for many years. In 1968, the first definition for pain was introduced by 
McCaffery as "whatever the experiencing person says it is, existing whenever and 
wherever the person say it does" (McCaffery, 1972, p. 11). This definition was vague as 
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there are no standard tools to assess pain, and it depends mainly on the description 
provided by the patient in their own words. 
The International Association for the Study of Pain (IASP) defines pain as an “unpleasant 
sensory and emotional experience associated with actual and potential tissue damage, or 
described in terms of such damage or both” (IASP, 2017, “Pain”, para. 1).  However, the 
relation between pain sensation and tissue damage is impractical to establish when guided 
by this definition (Price & Barrell, 2012).  
In 1999, Price proposed a new definition for pain as a somatic perception containing a 
bodily sensation with qualities like those reported during tissue damaging stimulation of an 
experienced threat associated with this sensation, and a feeling of unpleasantness or other 
negative emotions based on experienced threat. This update canceled the demand to 
correlate between tissue damage and pain sensation (Price & Barrell, 2012). 
In 2001, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) 
updated the definition of pain. This update included not only short-term hospitalized 
patients, but also included all different categories of long-term treated patients. Moreover, 
adverse physiological and psychological side effects related to unrelieved pain were added 
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1.2 Pain signalling 
It is fundamental to understand pain signalling mechanisms to understand some clues about 
the complex phenomenon of pain. The term “nociceptors” is derived from the Latin term 
"nocer", meaning injury or hurt; thus, receptors signalling noxious stimulus are called 
nociceptors and are present everywhere in the body.  
Recent studies have classified nociceptors into four types: (1) thermal nociceptors activated 
by high or low temperatures, (2) mechanical nociceptors activated by extreme pressure to 
the skin, (3) polymodal nociceptors are enabled by chemical, mechanical and thermal 
stimuli, and (4) silent, or sleeping nociceptors which are activated by inflammatory 
mediators (Lemke, 2004).  
Additionally, nociceptors have two major anatomical groups. The first group comprises of 
myelinated (Aδ) afferents, and is characterized by rapid onset, and mediate acute pain. The 
second group is the unmyelinated C fibers, which respond to both mechanical and thermal 
stimulus (polymodal), and demonstrate the slowest conduction (Willis, 1985). Additionally, 
neuroanatomical studies have shown that C fibers express the neurotrophin TrkA receptor 
which has high affinity to NGF (Fang et al., 2005).  
Upon nociceptor stimulation with any noxious stimulus (e.g., chemical, thermal, 
mechanical), signals are identified and conveyed through the primary afferent nociceptors 
to the brain, where they are encoded (Basbaum et al., 2009). The most common conception 
of this process involves pain being elicited in a unidirectional pathway from the area of 
stimulus to the spinal cord. In fact, afferent fibers have been named pseudo-unipolar, as 
studies have shown that both central and peripheral terminals share the same axonal origin. 
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In other words, nociceptors can communicate from either end (central or peripheral) 
(Basbaum et al., 2009). This morphological finding is valuable as it opened the door to 
different treatment options; pain can be controlled through the peripheral pathway (as 
topical drug applications) or at the central pathway (as intrathecal injections; Alexander et 
al., 2012; Nagano et al., 2005). Figure 1.1 outlines central and peripheral signalling 
pathways in response to noxious stimuli. 
 
 
Figure 1.1: Central and peripheral system pain signalling pathways in response to 
noxious stimuli. 
Upon nociceptor stimulation with any noxious stimulus signals are 
identified, and conveyed through the primary afferent nociceptors, where it 
is encoded. Image is originally published in Nature (Bingham et al., 2009). 
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1.3 Pain classification 
Over many years, physicians, researchers, practitioners, and pharmacologists have been 
trying to agree upon an accurate pain classification system to improve pain management 
and treatment. Unfortunately, pain classification is still confusing and is not reliable. 
Various pain classifications were introduced based on anatomical classification (where pain 
is classified according to body locations), or etiological classification, based on the etiology 
of the disease, neglecting any other factors such as duration, location, and pain intensity 
(WHO, 2012). 
The most commonly acceptable pain classification relies on pain duration, and is classified 
as follows: 
Acute pain: Acute pain is characterized by a rapid onset, and acts as an alarm system that 
detects any noxious stimuli. It usually lasts for a few days to a maximum of two to three 
months. It emanates as a result of tissue injury, and is relieved after tissue healing (Jones, 
2001).  
Chronic pain: Chronic pain is defined as “aberrant somatosensory processing in the 
peripheral or central nervous system (CNS) that is sustained beyond the normally 
expected time course relative to the stimulus” (Greene, 2010, p.5). However, this 
definition does not include all the variables affecting chronic pain. In fact, chronic pain is 
a multi-directional complex phenomenon; the patient with chronic pain is not deregulated 
only by the pathological effects, but chronic pain also deregulates different systems 
including but not limited to behavior, cognition and emotional responses (Greene, 2010). 
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1.4 Pain and its impact 
Pain is the most common medical complaint, but despite its prevalence, many individuals 
still suffer from chronic or untreated pain. According to a study done by Todd et al. 
(2007), pain is the most common reason for seeking healthcare, and it accounts for up to 
78% of emergency hospital visits. However, many Canadians are left to suffer varying 
degrees of pain with little to no medical attention.  
Despite having the knowledge and technology to help some of them, we still see many 
cases that cannot be treated by the means that we know of now. In 2008, the University 
of California conducted a survey to analyze the correlation between the impact of pain 
and quality of life of pain sufferers, and the different options of pain management 
(McCarberg et al., 2008). In addition, physicians were asked to identify the challenges 
faced when treating a patient’s pain. The results of the survey showed that the chronic 
pain sufferers experienced multiple negative effects, which may severely impact their 
whole life. These effects included, but were not limited to: functional impairment and 
disability, anxiety, depression, sleep deprivation, and perhaps even their employment 
status and their ability to fulfill their basic duties (McCarberg et al., 2008).  
The physician’s survey indicated that pain management is a major health challenge, 
especially when taking into consideration the addiction problems that some patients face, 
the side effects associated with pain management medications, and the effects of dose 
withdrawal (Al-Hasani & Bruchas, 2011; McCarberg et al., 2008). Studies also showed 
that people experiencing chronic pain are two times more likely to commit suicide 
compared to people without chronic pain (Tang & Crane, 2006). While a wide range of 
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therapeutic treatments are available, none of these are satisfactory.  
1.5 Genetic defects in pain perception 
According to the orthopaedic surgeon Paul Brand and authors (1993) in his book The Gift 
Nobody Wants, “pain is not the enemy, but the loyal scout announcing the enemy” (p. 
20). Pulling your hand away when touching a hot surface is a protective mechanism 
because the hot surface causes you pain. However, individuals with hereditary sensory 
and autonomic neuropathies (HSANs) can have their hands burned, or can have broken 
legs without being aware, due to their inability to perceive pain. Despite the fact that 
hereditary sensory and autonomic neuropathies are rare, it is important to develop an 
understanding of them, as they can provide us with more information about the diversity 
and complexity of our nervous system. 
HSAN is classified into five different types. Understanding molecular pathology for 
HSAN type IV is of significant advantage to explore the role of NGF-TrkA signalling. 
HSAN type I: it is demonstrated between the second and fourth decade with ulcers at 
lower extremities, atypical pain and thermal perception, and anhidrosis (Hilz, 2002). 
HSAN type II: it is recognised by impaired autonomic dysfunction and severe sensory 
impairment (Hilz, 2002). 
HSAN type III: it is the most common type of HSAN’s; it is known as familial 
dysautonomia. This disorder significantly alters the autonomic and sensory system (Hilz, 
2002). 
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HSAN type IV: it is also known as “congenital insensitivity to pain and anhydrosis” 
(CIPA). CIPA is an autosomal recessive hereditary disorder, characterized by absence of 
pain perception to mechanical stimuli, anhydrosis, and recurrent episodes of fever as 
anhydrosis causes deregulation of homeostasis. Electrophysiological studies including 
nerve conduction and a set of experiments have been done in a trial to pinpoint the 
defects. The results indicate absence of small mylineated and unmyelinated fibers with 
the presence of the natural large myelinated fibers (Goebel et al., 1980).  
In 1986, a novel gene coding for the cell surface receptor tyrosine kinase family (Trk) 
was isolated from human colon carcinoma (Martin-Zanca et al., 1989). Studies have 
since proven high affinity binding of NGF to TrkA, which is then phosphorylated upon 
binding and plays a fundamental role for intracellular signal transduction (di Mola et al., 
2000).  
TrkA knockout mutant mice have shown serious sensory and sympathetic neuropathies. 
Moreover, the mutant mice were born smaller in size and died within one month of birth 
(Crowley et al., 1994). Gathering all this information starting with the 
electrophysiological findings, and comparing CIPA with TrkA knockout mice, it has 
been shown that they both share severe impairment in sensory and sympathetic neurons, 
and insensitivity to any noxious stimulus. All this data suggest that TrkA gene mutation 
is the cause of CIPA (Indo, 2001). 
Many of the TrkA signalling roles with NGF are still unstudied. Studying molecular 
pathology for CIPA is of significant advantage to explore the role of NGF-TrkA 
signalling. 
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HSAN type V: it is recognized within a few months after birth with selective loss of pain 
perception despite having a normal neurological response (Hilz, 2002). 
1.6 Pharmacotherapeutics pain management 
Chronic pain management is a challenging task. For many years, treatment was directed to 
the pathological cause with the assumption that the pain would be relieved. However, in 
many cases, even a combination of different medications would not help in the relief of 
pain.  
As a step to improve pain treatment, in 2005, the Canadian Council on Health Services 
Accreditation added pain assessment and management in the Achieving Improving 
Measurement Standards (Accreditation Canada, 2013). 
General pharmacotherapeutic strategies have been established to manage chronic pain. 
There are three major classes of medications used in chronic pain management: NSAIDs, 
acetaminophen and opioids. The mechanisms and side effects for these are discussed 
below: 
1.6.1 Nonsteroidal anti-inflammatory analgesics (NSAIDs) 
Following the pharmacotherapeutic principles, mild to moderate pain is treated with non-
steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen and indomethacin. 
The anti-inflammatory and analgesic mechanism of action for NSAIDs is by the inhibition 
of cyclo-oxygenase (COX) enzyme, which enables prostaglandin release. Prostaglandins 
have a significant role in stimulating the inflammatory response, as shown by the major 
changes in prostaglandin production during inflammation (Ricciotti et al., 2011). 
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Gastric and intestinal mucosal defense mechanisms and renal blood flow regulation are one 
of the physiological roles of the COX enzyme. Despite the effectiveness of NSAIDs in pain 
management, blocking COX enzyme causes a number of side effects, including gastric 
complications which can vary from gastric ulcer to gastric haemorrhage, renal dysfunction 
and increased risk of myocardial infarction (Marcum & Hanlon, 2010; Peskar, 2001). 
1.6.2 Acetaminophen analgesics 
The mechanism of action of acetaminophen is still unknown. Acetaminophen has an 
analgesic and antipyretic effects. While recognized as a safe drug, it may have a rare but 
mild side effect, including abdominal pain or diarrhea. Acetaminophen is contraindicated 
for patients with liver disease, as hepatic toxicity can be fatal (Lynch & Watson, 2006). 
Moreover, acetaminophen has a ceiling effect; so increasing the dose does not necessarily 
enhance its effectiveness (Hinz et al., 2008).  
1.6.3 Opioid analgesics 
Central and peripheral nervous systems produce natural endogenous opioids, which have a 
role in pain signalling. There are three groups of opioids receptors; µ, κ and δ. Most opioids 
antagonists have a considerably high affinity to opioid receptors through which they block 
their actions (Al-Hasani & Bruchas, 2011).  
Opioid treatments have a broad range of side effects such as constipation, sedation, nausea 
and vomiting. Moreover, opioid treatment has the high risk of addiction and respiratory 
depression (Park & Moon, 2010). Unfortunately, despite all efforts, the quest for a safe and 
effective pain relief medication has not yet been achieved. 
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1.7 NGF discovery, and its role 
With the discovery of NGF as a pain mediator, agents targeting NGF receptors or its 
signalling pathway can provide a new area to explore in therapeutic pain management with 
the potential of no adverse effects.  
NGF was discovered by Rita Levi-Montalcini in the 1950’s (Aloe et al., 2004) as a 
“survival factor for sensory and sympathetic neurons in the developing nervous system” 
(Lötsch & Geisslinger, 2011, p. 453). Levi-Montalcini was interested in studying nerve 
development in chick embryo. She observed that if she cultured a tumor cell line anywhere 
in a developing chick embryo, the nerve fiber would grow more rapidly than the normal 
embryo (Aloe et al., 2004). 
In 1952, she speculated the presence of a biochemical agent that was capable of inducing 
the growth of nerve fiber. To study this agent further, she worked with Dr. Cohen to 
understand the workings of this biochemical agent. After a set of several experiments, they 
came to the discovery of the signalling protein NGF (Aloe et al., 2004) .  
Levi-Montalcini and Cohen were able to produce significant amounts of purified mouse 
salivary NGF as well as antibodies against NGF. Through sets of experiments, they were 
able to discover the function and significance of NGF in the development of sensory and 
sympathetic ganglia (Bocchini & Angeletti, 1969). In 1986, Levi-Montalcini was 
awarded the Nobel Prize in Physiology or Medicine for this discovery (Cowan, 2001). 
Figure 1.2 outlines different experimental sets to discover NGF. 
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Figure 1.2: Experimental trials for NGF discovery.  
Chicken embryo nerve tissue cultured with (1) control medium (Upper Left), 
(2), crude snake venom (Upper Right) (3), a partially purified protein 
fraction of snake venom (Lower Left), and (4) the protein fraction purified 
from sarcoma  (Lower Right). Image is originally published in Proceedings 
of the National Academy of Sciences of the United States of America 
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Until recently, it was believed that NGF’s sole role was to act as a survival factor for 
sensory and sympathetic neurons in the developing nervous system. Recent studies have 
shown that NGF’s role is much more extensive and is crucial even beyond the nervous 
system (Petty et al., 1994). One of their crucial findings was NGF’s role in mediating 
inflammatory and immune response after tissue injury (McMahon, 1996). Furthermore, 
increased levels of proNGF (NGF precursor) has been found in neurodegenerative 
diseases such as Alzheimer and Parkinson’s (Lorigados Pedre et al., 2002; Williams et 
al., 2006). These findings can help in the development of new therapeutic strategies in 
the treatment of chronic pain and neurodegenerative diseases. 
1.8 Biological development of the NGF in the nervous system 
The development of synaptic connections with different cells begins during the early 
developmental stages. During this period, the axons extend from the neurons to their 
targets. As the development process is happening, it is expected that minimal cell death 
occurs. Unexpectedly, massive cell death occurs, and more than 50% of the neurons 
undergo cell death. The only accepted explanation that this programmed cell death 
provides more vast and more efficient nervous system (Frade & Barde, 1998). 
Later developmental stages are characterized by target innervation. A unique feature for 
NGF, in comparison to other neurotrophins, is that it has two receptors with opposite 
actions. TrkA maintain neural survival, and p75 is an apoptotic inducer. During this 
stage, p75 enhances NGF binding to TrkA to maintain cell survival. During adulthood, all 
neurotrophins function to promote neural plasticity. During this period, NGF enhances 
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neurotransmitter expression during inflammation to perceive noxious stimuli (see Figure 
1.3; Dekkers et al., 2013). 
 
Figure 1.3: The Biological action of NGF in the developing and adult nervous 
system. 
In newborn, NGF triggers the elimination of newly born neurons expressing 
p75. At later developmental stage, NGF and other neurotrophin express the 
appropriate TrkA receptors to maintain neuronal survival. In adulthood, 
NGF modulates neuronal plasticity and is involved in the regulation of 
hyperalgesia during inflammation. This picture is originally published in 
BioEssays (Frade & Barde, 1998). 
Chapter 1: Introduction 
15 
1.9 NGF structure 
It is crucial to understand the molecular structure of NGF and its receptors, so that we are 
able to design antagonists. This will pave the way to develop pharmacological and 
biological agents that will antagonize NGF mediated pathologies.  
NGF is a member of the neurotrophin family. They are large protein molecules produced 
by target cells. They enable cell survival, differentiation, and neurite outgrowth (Korsching, 
1993). Recent studies have shown that the neurotrophins have other fundamental functions 
including the promotion of synaptic plasticity, neuron protection and repair after tissue 
injury (Figure 1.3; Berry et al., 2012; Boyd & Gordon, 2003).  
NGF structure was first discovered by X-ray crystallography, as a novel protein fold. NGF 
is composed of two 12.5 kDa monomers, and each monomer is composed of 118 amino 
acids (Angeletti & Bradshaw, 1971).  
The three-dimensional structure of NGF was first identified in 1991 (McDonald et al., 
1991). It is composed of antiparallel β strands folded around each other forming an 
elongated structure. β-hairpin structures are located at one end of the three-loop molecule, 
while the opposite end contains cysteine-knot. This arrangement stabilizes the fold and 
preserves the molecular structure (Bradshaw et al., 1994). Studies have revealed a 
substantial variety in the loop region that differentiates NGF from the other neurotrophins 
(Wiesmann et al., 1999). Moreover, loop regions play a crucial role in receptor 
identification and binding. While Loop I, II, and IV are essential for TrkA binding, loop I 
and V are responsible for p75 binding (see Figure 1.4 ; Barker, 2007). These findings led 
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researchers and pharmacologists to target these specific loop regions in the NGF in 
attempts to inhibit NGF or its signalling pathways.  
 
Figure 1.4: NGF structure. 
The three-dimensional structure of NGF shows β-hairpin structures located 
at one end of the three-loop molecule. While the opposite end contains 
cysteine-knot. Moreover, it shows different loop regions suggested to be 
targeted by small molecule inhibitors. This picture is published in 
Neurochemistry International (Eibl et al., 2012). 
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1.10 NGF receptors 
For many years, p75 was believed to be the only receptor for NGF until the discovery of 
the TrkA receptor function. p75 is a transmembrane glycoprotein. It binds with almost 
the same equimolar affinity to all neurotrophin members. p75 is a member of the tumor 
necrosis receptor family (Bigda et al., 1994). Although p75 acts as an apoptosis inducer, 
studies have shown that it also has a role in neuronal cell survival and differentiation 
(Truzzi et al., 2011; Verdi et al., 1994). Upon stimulation of p75 expression, it leads to 
increase tyrosine phosphorylation of TrkA and potentiates cell survival and 
differentiation induced by NGF (Verdi et al., 1994).  
TrkA is a single-path transmembrane glycoprotein. It is a member of tyrosine kinase 
growth factor receptors, and it plays a fundamental role in maintaining synaptic strength 
and plasticity of the nervous system (Kaplan & Stephens, 1994). TrkA binds to NGF with 
high affinity, and upon binding, Trk tyrosine kinases are activated and enable Ras 
stimulation. Ras, in turn, promotes activation of the mitogen-activated protein (MAP) 
kinases, and PI3K/Akt signalling pathways (Huang & Reichardt, 2001). 
Although both receptors can function independently to bind to NGF, the decision between 
survival and death among NGF responsive neurons may be determined by the ratio of p75 
to TrkA receptors (see Figure 1.5; Barrett & Bartlett, 1994). 
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Figure 1.5: NGF receptors TrkA and p75. 
TrkA activation leads to antiapoptotic signals that dominate over apoptotic 
signals of p75. The green arrow is survival, and the black arrow is 
programmed cell death through activation of p75. This figure is published in 
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1.11 NGF response to inflammation 
Increased levels of NGF have been reported in a variety of acute and chronic diseases, 
including cystitis, rheumatoid arthritis, prostatitis and endometriosis (Barcena de Arellano 
et al., 2011; Barthel et al., 2009; Chen et al., 2016; Miller et al., 2002).  
Following injury, the damaged tissue and the activated immune cells release inflammatory 
mediators. Mast cells, macrophages, and T cells all stimulate NGF release, which in turn 
binds to its receptors: TrkA and p75. The release of NGF results in the stimulation of many 
intracellular signalling pathways, leading to a variety of different cellular responses. Once 
binding occurs, the TrkA-NGF complex is transported to the cell body where it stimulates 
multiple gene expressions (see Figure 1.6; Nicol & Vasko, 2007). 
 
Figure 1.6: NGF response to inflammation, stimulating intracellular signalling and 
gene expression. 
Following injury, the inflammatory mediators stimulate NGF release, 
causing activation of different cellular response. This figure was published in 
Molecular Interventions (Nicol & Vasko, 2007). 
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1.12 NGF and therapeutic interventions 
NGF signalling has a very critical and valuable effect on neuronal protection and repair, 
which opens up the possibility for developing new therapeutic methods. However, due to 
the wide range of cells that respond to NGF signalling, many unwanted side effects may 
arise (Longo et al., 1999; Mantyh et al., 2011). 
For example, in a study that was run for the safety of intravenous or subcutaneous NGF 
administration, patients suffered from sustained hyperalgesia (Andersen et al., 2008). 
Dysregulation of NGF signalling also has been reported in diabetic patients (Ji et al., 2002). 
Recombinant human NGF (rhNGF) has been tested in patients with diabetic neuropathy; it 
resulted in the same side effects such as hyperalgesia, and myalgia, and this clinical trial 
was terminated (Apfel et al., 2000). 
One of the greatest challenges for NGF treatment is its inability to cross the blood brain 
barrier when administrated systemically. For this reason, another trial has been performed 
through the infusion of NGF into the cerebroventricular system of Alzheimer’s patients. 
This also resulted in back pain after the infusion (Aloe et al., 2012).  
1.12.1 Human anti-NGF monoclonal antibodies 
Due to these side effects, several approaches have been tried either by antagonizing NGF or 
blocking its binding to TrkA, which in turn can inhibit TrkA signalling. Several 
interventions have been undertaken for NGF inhibition in vivo. One of these trials used 
anti–NGF antibodies. This study involved testing analgesic and safety effects of human 
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monoclonal anti-NGF antibodies in adult osteoarthritic patients. These include Fulranumab, 
Tanezumab, and Fasinumab (Seidel et al., 2013; Tiseo et al, 2014).  
Although these drugs seemed promising in relieving pain in osteoarthritic patients, the 
trials were discontinued as patients were experiencing rapid joint destruction among other 
side effects (Seidel et al., 2012). 
1.12.2 Mimetic peptides 
Studies were directed to inhibit NGF-TrkA complex using NGF mimetic peptides. Many 
efforts have been devoted in an attempt to synthesize small molecules which mimic or 
antagonize NGF (Colangelo et al., 2008). Mimetic peptides are synthetic peptides that 
consist of short sequences of amino acids (5-10) resembling regions in NGF domains. 
Their mechanism relies on competing with NGF for its binding sites and blocking its 
signalling pathway (Beglova et al., 2000). Many of these studies were promising, and it is 
hoped that they will have positive results in relation to second and third generation 
therapeutics with no side effect and more potency (Eibl et al., 2012). 
1.12.3 Small molecule inhibitors 
The neurotrophins share many commonalities with dimeric proteins in terms of structure 
and chemical properties (Robinson et al., 1995). Studies have reported a fundamental 
variety in the loop region that differentiates NGF from the other neurotrophin members 
(Wiesmann et al., 1999). These findings lead researchers and pharmacologists to target 
this specific loop region in the NGF in attempts to inhibit NGF or its signalling pathway 
using small molecules inhibitors (see Figure 1.4). The small size of the molecule will 
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easily occupy NGF structure, altering NGF topology, thus inhibiting NGF signalling 
pathway (Niederhauser et al., 2000). 
Recent studies have reported small molecule inhibitors, which have shown inhibition of 
NGF signalling. These include, PD90780, ALE 0540, and Ro 08-2750 to name a few 
(Eibl et al., 2010; Niederhauser et al., 2000; Owolabi et al., 1999; Spiegel et al., 1995). 
These small drug-like molecules have the ability to bind and modify NGF by inhibiting 
NGF/TrkA and NGF/p75. Their small size is of great value as they potentially could be 
administered orally, and may cross the blood brain barrier. This feature will provide a 
great advantage in treating central nervous system pathologies. Moreover, the ability of 
these compounds to act as inhibitors of NGF and proNGF has been tested using (SPR) 
surface plasma resonance spectroscopy (Sheffield et al., 2015).  
In this study, PD90780 was selected to assess its ability as a known NGF inhibitor in 
PC12 cell line. PD90780 is a non-peptide NGF inhibitor. It was first determined to inhibit 
binding of NGF to the p75 receptor by targeting loops I/IV cleft of NGF (see Figure 1.4; 
Spiegel et al., 1995). A more recent study by Sheffield et al. (2016) used plasma 
resonance technology to demonstrate that PD90780 is the most effective inhibitor for 
TrkA and p75 receptors among the reported small molecules inhibitors. Moreover, 
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1.13 NGF and regulation of gene expression 
Advances in the fields of molecular and cell biology, and the massive data acquired from 
gene expression analysis have helped to gain a better understanding of cell signalling, 
function and response. Better understanding of genetic networks will contribute to identify 
novel drug targets, and more sensitive diagnostic strategies.  
In 2000, studies were conducted by Angelastro et al. to explore how NGF regulates gene 
expression in neurons using serial analysis of gene expression (SAGE). The studies have 
identified hundreds of genes, which can be expressed or depressed after the exposure to 
NGF. Additionally, they focused on transcription factors that control gene function. In 
response to a range of external stimuli, a study by Sheng and Greenberg (1990) showed 
that early gene expression response was rapidly induced even in the absence of protein 
synthesis, such as Egr-1, c-fos, and c-jun. In this study, Egr-1 gene has been chosen to 
assess the signalling response of NGF and the effect of the inhibitory compounds in NGF 
treated cells. 
1.13.1 Egr-1 discovery 
Early growth response protein 1 (Egr-1) is a member of the immediate early gene family; 
it is rapidly induced within minutes after stimulation and it also rapidly decays (Mokin, 
2005). When Egr-1 was first discovered in the mid-eighties, it was originally named 
nerve growth factor inducible A (NGFI-A). The name was given based on the fact that 
Egr-1 or NGFI-A is expressed in response to NGF stimulation of PC12 cells in the neural 
cell differentiation model (Milbrandt, 1987). Later on, it was reported in studies that were 
aimed at finding genes that contribute to growth, proliferation and differentiation of cells. 
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Following studies conducted on stimulated murine and human fibroblasts, the new name 
“Egr-1” was introduced by Sukhatme et al. (1987). 
Recent studies have reported that Egr-1 is rapidly expressed in differing cellular 
responses such as: growth factors, stress, irradiation, injuries, neural plasticity and 
cytokines (Duclot & Kabbaj, 2017; Granet & Miossec, 2004; Lim et al., 1998; Sukhatme 
et al., 1988; Virolle et al., 2001; Wu et al., 2009). Moreover, NGF is known to induce 
expression of Egr-1 (Kendall et al., 1994). 
1.13.2 Egr-1 gene downstream regulation 
Egr-1 is a nuclear protein encoded by zinc finger transcription factor of Cys2-His2 class 
for 80 - 82 kDa (Thiel et al.,1994). The Egr-1 transcription factor is composed of 
independently operating domains: the activation domain and DNA binding domain. 
While the activation domain is located at the N terminal region, the DNA binding domain 
is located at C terminal region. DNA binding domain is composed of three-tandem zinc-
finger, where it combines with their target molecules. Moreover, a repressor domain has 
been determined on the Egr-1 protein and it is positioned between the activation domain 
and the DNA binding domain (see Figure 1.7; Christy & Nathans, 1989). The repressor 
domain plays a crucial role in controlling gene overexpression by binding to NAB2 co-
repressor leading to inhibition of its own downstream signalling and blocking its 
signalling pathway (Russo et al., 1995). 
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Figure 1.7: Functional domains in Egr-1 transcription factor. 
The Egr-1 transcription factor structure is composed of an activation domain 
located on the N terminus and the three-tandem zinc finger located at the 
DNA binding domain. Moreover, an inhibitory domain in between the 
activation and the DNA binding domain. The figure was published in Journal 
of Cellular Physiology (Thiel & Cibelli, 2002). 
 
1.13.3 Egr-1 and MAPK signalling 
Egr-1 gene has a pivotal role in many biological functions, from regulating cell growth, 
to proliferation and cell survival (Nguyen et al., 1993). The Egr-1 transcription regulator 
is characterized as a “master switch”, as it acts as the connecting switch between the wide 
range of extracellular stimuli and the activation of the target gene (Yan et al., 2000). 
Studies have reported that Egr-1 is induced in a wide range of cell types involved in the 
mitogen process (Peng et al., 1999). Moreover, mRNA for Egr-1 was synthesized in 
response to platelet derived growth factor, transforming growth factor and insulin like 
growth factor which are released on the activation of the mitogen activated protein kinase 
(MAPK) signalling cascades (Gineitis & Treisman, 2001).  
The MAPK signalling pathway involves a series of proteins that act as convergent points.  
These convergent points work by transmitting signals on the cell surface from an 
extracellular stimulus until the signal translocates to the nucleus of the cell. The MAPK 
pathway structure is simply comprised of G proteins (RAS), and three consecutives 
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protein kinases (RAF, MEK and ERK). Kinases are enzymes that transfer phosphate 
groups to particular amino acids of a target protein. 
The binding of extracellular stimuli, such as pathogens, stress or injury to the cell 
receptor, acts as a starting point that triggers all the signalling cascades. A ligand binding 
to its receptor causes dimerization of two-receptor tyrosine kinase subunits. This, in turn, 
stimulates phosphorylation and catalyzes the exchange of guanosine diphosphate (GDP) 
to guanosine triphosphate (GTP), changing the dormant RAS protein that binds to GDP 
to the active form of the RAS protein. Thus, active RAS protein phosphorylates, and 
activates the kinases RAF, MEK and ERK. Once ERK is activated, it translocates to the 
nucleus and activates several gene transcription factors such as Egr-1 transcription factor, 
and subsequent activation of genes expressions (see Figure 1.8; Zhang et al., 2002).  
Apparently, a wide range of extracellular stimulus can induce Egr-1 gene expression 
(Nguyen et al., 1993). Knowing the fact that NGF is an Egr-1 gene inducer (Kendall et 
al., 1994), and that Egr-1 transcription factor acts as a “master switch” was of great value 
(Laity et al., 2001). Taking this into consideration, it can be suggested that NGF 
signalling and the effects of NGF inhibitory molecules can be evaluated by examining 
this “master switch”: Egr-1 gene expression. This means that the role of the Egr-1 gene in 
this study can be used as a marker to assess NGF signalling, to help us determine whether 
it is on or off.  
Studying gene expression is a useful tool to help us gain a better understanding of the cell 
signalling response, which, in turn, can be useful in the discovery of novel drug targets. 
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Taking all of this information altogether, further research is needed to optimize the 
therapeutic potential of NGF inhibitors. 
 
 
Figure 1.8: MAPK signalling pathway. 
Binding of the extracellular stimuli to its ligand triggers the signalling 
cascades for MAPK pathway. Starting from RAF, REF, MEK to ERK. After 
ERK is translocated into the nucleus, transcription factor induces gene 
expressions. This figure was adapted from Molecular Cell Biology. 
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1.14 Neural cell line (PC12) 
To have a better understanding of the NGF riddle, investigate NGF mechanism and 
explore different therapeutic interventions, a successful neural differentiation model 
should be applied. The most commonly used models in neural cell differentiation are 
either the primary cell culture or a neural cell line. The PC12 cell line is one of the mostly 
widely used models in neural cell differentiations. It was refined in 1976 by Greene and 
Tishler from adrenal medulla tumour of a rat.  
PC12 cells share the same embryological origin with neuroblastic cells. Despite the fact 
that they share the same criteria of neurons, they are not considered as neuron. A 
distinguishable feature of PC12 cells is that they convert from chromaffin like cells to 
neuron like cells with dendritic extensions in response to NGF treatment (Eaton & 
Duplan, 2004).  
The PC12 cell line was selected to investigate the effect of NGF inhibitory molecules. It 
is a straightforward and a useful model for in vitro studies. Its value relies on evaluating 
the results obtained from PC12 and deciding the following steps in investigating it in 
primary cell culture. Levkovitz et al. (2001) established that PC12 cells demonstrate a 
distinct expression of the Egr-1 gene when stimulated by NGF. 
1.15 Phorbol 12-myristate 13-acetate (PMA) 
Phorbol was first reported in 1934 as a product of the hydrolysis of cotton seeds. PMA is 
a diester of phorbol that has a controversial effect (Bueso et al., 2016). While they are 
recognized by their ability to act as a tumour activator by inducing cell apoptosis, studies 
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have also reported its role in angiogenesis, and various effects in many cellular activities 
and different signalling pathways (Davis & Lipsky, 1985; Park et al., 2001). 
Angiogenesis and cell proliferation are modulated by activating the Protein C kinase 
signalling pathway (Caino et al., 2011). 
Further studies have reported that PMA can stimulate the signalling pathway of MAPK, 
and is a potent mitogen that can induce different gene expressions (Chiu et al., 1987). 
Moreover, induction of immediate early genes in response to PMA, such as c-fos, c-jun 
and Egr-1 gene has been also reported (Dunnmon et al., 1990). 
Cheng et al. (1994) found that, when treated with PMA, Egr-1 expression in PC12 cells is 
induced with peak expression 1 hour after treatment (Cheng et al., 1994). For this reason, 
PMA was chosen as a positive control for Egr-1 gene expression. 
1.16 Gene analysis technique 
For decades, biologists have used many tools, such as Northern or Southern blotting, to 
quantitate nucleic acids. In 1997, the Northern blot technique became a popular method for 
RNA quantification. The main idea for the Northern blot is to separate RNA according to 
their molecular size using a complementary hybridization probe (Alwine et al., 1977). 
However, it is a complex, and time-consuming procedure. Additionally, there is an 
increased risk of toxicity by the chemicals used for RNA denaturation, which makes this 
procedure unsafe to use (Goda & Minton, 1995). More attention was needed to generate 
more sensitive and specific quantification methods. 
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Nowadays, reverse transcriptase polymerase chain reaction (RT-PCR) is used as a standard 
tool for gene analysis. The invention of PCR by Kary Mullis in 1989 dramatically changed 
every scientific aspect (Mullis, 1990). This discovery made the impossible possible. PCR is 
a sensitive and a straightforward technique. The major strength of this technique is that 
small amount of RNA can be copied and amplified by PCR. Then, it can be quantified to 
analyze different gene expression.  
Amplification of small amount of RNA has a tremendous impact in many scientific 
branches such as infectious disease detection, the discovery of different gene mutation, and 
forensic investigations. Moreover, PCR helped to solve the mystery of certain diseases in 
the past. For example, in 1967, the former vice president and presidential candidate Hubert. 
H. Humphrey had negative test results for bladder cancer, but passed away in 1978. When 
a urine sample was tested with PCR in 1990, surprisingly the results were positive for 
bladder cancer. The PCR technique is the invention for the past, present, and future. In 
1993, Mullis won Nobel Prize in Chemistry for the PCR invention (Powledge, 2004). 
In this study, we use gene expression analysis as functional readout, to assess the effect of 
the inhibitory compounds in NGF treated cells applied. Furthermore, Egr-1 expression time 
course is determined for Egr-1 in NGF treated PC12 cells. All the results were analyzed by 
semi quantitative RT-PCR. 
1.17 Hypothesis and objectives 
1.17.1 Hypothesis 
Expression of genes downstream of NGF signalling can be used as an effective screening 
strategy for evaluating NGF inhibitors. 
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1.17.2 Objectives 
i. Identify the peak time for Egr-1 expression in NGF treated cells. 
ii. Determine the gene expression of Egr-1 in NGF treated cells in the presence of NGF 
inhibitors using semi quantitative RT-PCR. 
1.17.3 Rationale 
Chronic pain management is a challenging task. To date, many cases cannot be treated by 
the currently available techniques. Despite all the efforts done, the quest for safe and 
effective pain relief medications have not yet been achieved.  
With the discovery of NGF as a pain mediator, studies were directed towards targeting 
NGF receptors or its signalling pathway. It is known that NGF release will induce 
different gene expression including Egr-1 gene. Exploring Egr-1 gene expression in NGF 
treated cells and comparing them to cells treated with NGF inhibitors may provide a 
better understanding of the NGF signalling riddle. Moreover, it may help to identify a 
novel drug target with the potential of no adverse effects. 
1.18 Thesis organization 
Chapter 2 focuses on the methodology and the materials used to run all the experiments. 
Chapter 3 presents the results obtained using semi quantitative PCR technique. Chapter 4 
provides discussion and analysis of the results. Finally, Chapter 5 provides the conclusions 
derived from this thesis and highlight the major directions to extend this research in the 
future. 
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Chapter 2  
 
This chapter outlines the materials and the methodology used to run all the experiments. 
While the first step focuses on different treatments applied to cells, the second one deals 
with RNA extraction and DNAse treatment. Finally, PCR reactions will be analyzed. 
2.1 Cell culture 
PC12 cells were cultured in Dulbecco’s Modified eagle Medium (DMEM), supplemented 
with 10% fetal calf serum (FCS) (Gibco; USA), 0.1 U/ml of penicillin and 0.1 U/ml of 
streptomycin. All cells were maintained at 37°C in a humidified incubator in 5% CO2-95% 
air. The cells were grown to 80% to 90% confluence in T 75 cm2 tissue treated flasks 
(Corning-USA). Using trypsin, (Trypsin-EDTA, Gibco; Canada), cells were dissociated. 
The cells were then counted and their viability was determined using a cell viability 
analyzer (Vi-cell XR, Beckman Coulter; Mississauga, Ontario) before being plated into 6 
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2.2 Cell treatments 
2.2.1 First objective 
Cells were treated with 0.5 nM of NGF obtained from Cedar Lane Labs (Burlington, ON, 
Canada), or 80 nM PMA (Sigma- Aldrich; Canada) for 30, 45, 60, 90 and 180 minutes. 
2.2.2  Second objective 
NGF treatment 
Cells were treated with 0.5 nM of NGF and 100 µM of PD90780 obtained from Sussex 
Research (Ottawa, ON, Canada). NGF was pre-incubated with PD90780 for 60 minutes, 
and then the cells were incubated with the mixture for another 90 minutes. 
PMA treatment 
Cells were treated with 100 µM of PD90780, and 80 nM of PMA positive control. PMA 
was pre-incubated with PD90780 for 60 minutes, and the mix was incubated for another 60 
minutes with the cells. All the samples were done in 6 replicates. 
2.3 RNA extraction 
Total RNA was extracted from the treated cells with TRIZOL reagent (Sigma-Aldrich), 
following the manufacture’s protocol as follows. The media was removed; 500 µl of 
TRIZOL reagent was added to each well of the 6 well plates, for cell lysis. Cell lysates 
were transferred into an Eppendorf tube, followed by adding 100 µl of chloroform. The 
samples were then vortexed, and incubated at room temperature for 10 minutes. Samples 
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were centrifuged at 12,000 x g for 20 minutes at 4°C. The aqueous phase (top layer) was 
transferred into clean tube.  
RNA was precipitated by adding 125 µl of isopropanol, then vortexed, and incubated at 
room temperature for 10 minutes. The samples were once again vortexed, before being 
centrifuged at 12,000 x g at 4°C for 8 minutes. RNA pellets were washed in 250 µl of 70% 
ethanol, centrifuged at 7,500 x g for 5 minutes at 4°C. Ethanol was then removed, and 
RNA pellets were air dried and dissolved in 17 µl of RNase free DEPC (diethyl 
pyrocarbonate-treated H2O) at 37°C for 10 minutes. 
2.4 Quantification of RNA concentrations 
The quantification method was performed using a Nanodrop ND-1000 spectrophotometer 
at 260 nm. All measurements were carried out following the manufacturer’s instructions, 
and by using a 1 µl sample. The ratio of absorbance at 260 nm and 280 nm was used to 
assess the purity of RNA. A ratio far from 1.8 - 2 gives an indication of contamination. 
2.5 RNA integrity 
RNA integrity was analyzed by using denaturing RNA electrophoresis. Agarose gel was 
prepared using 1% agarose and 1X Tris–borate electrophoresis buffer (TBE-Maniatis 
protocol). Ethidium bromide (0.5 µg/ml) was added to the liquid agarose mixture before 
being casted. After loading the samples, the gel was left to run for 60 minutes at 90 Volts.  
RNA samples were prepared to a total volume of 12 µl by mixing 500 ng of the total RNA 
with 2 µl of 6X loading dye (Sigma- Aldrich) and DEPC water. 1 Kb plus DNA ladder 
(Sigma-Aldrich) was used as a molecular marker. RNA quantities and integrities were 
 Materials and Methodology 
35 
analyzed using Nanodrop ND-1000 spectrophotometer (Biorad). After gel electrophoresis, 
RNA integrity bands were evaluated visually by comparing (28S to18S) bands intensity. 
The 28S band intensity should be twice as intense as the 18S bands 2:1 ratio (28S: 18S). 
Intact bands are an indication that the RNA is intact. 
2.6 DNAse treatment  
RNA samples were treated with DNAse before reverse transcriptase to remove all genomic 
DNA that could be present. The protocol was as follows: 2 µg of RNA was used as a 
template for reverse transcriptase in a total of 50 µl final volume. RNA samples were 
treated with the following; 2 µl of DNAse reaction buffer (20 mM Tris-HCl and 20 mM of 
MgCl2) (Sigma –Aldrich), 2 µl of amplification Grade DNAse (Sigma –Aldrich), and 
DEPC-water to a final volume of 20 µl, followed by incubation at room temperature for 15 
minutes. 2 µl of Stop solution (50 mM EDTA) was added to terminate the reaction, and 
then heated for 10 minutes at 70°C. 
2.7 cDNA synthesis 
First strand cDNA was synthesized by reverse transcriptase, to get single stranded 
complementary DNA. This cDNA in turn can be used directly as a template for further 
amplification using PCR technique. M-MuLV (Moloney Murine Leukemia Virus) reverse 
transcriptase was used following the manufacturer’s instructions (Promega-Thermo Fisher 
Scientific Canada); as follows: random primers (1µl of 1 µg/µl) were added to the DNAse 
treated samples. The samples were heated for 5 minutes at 70°C, and then cooled on ice. 
Master mix was added to the samples, containing 2.5 µl of dNTPs (10 mM), 10 µl of 5X 
reaction buffer M-MuLV (Sigma-Aldrich), 12.5 µl of DEPC water and 2 µl of M-MuLV 
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RT to a total volume of 27 µl. The samples are then incubated for 60 minutes at 37°C using 
a thermo cycler (BioRad). 
2.8 Polymerase chain reaction (PCR) 
PCR was performed to amplify Egr-1 and β-actin genes using first strand cDNA as a 
template. The cDNA was synthesized from RNA isolated from PC12 cells as described in 
(Section 2.3).  For PCR protocol, GoTaq flexi DNA polymerase chain reaction kit 
(Promega) was used following the manufacturer’s instructions. The amplification 
reactions were performed using 2.5 µl of cDNA samples (0.05 µg/µl) that were added to 
a master mix prepared to a final volume of 25 µl. The master mix was prepared using the 
following; 0.5 µl of dNTPs (200 µM), 1.5 µl of MgCl2 (1.5 mM), 5 µl of GoTaq flexi 
polymerase reaction buffer (Sigma-Aldrich) (1X), 0.5 µl of forward primer (100 ng/µl), 
0.5 µl of reverse primer (100 ng/µl), 0.125 µl of GoTaq polymerase enzyme (5 U/µl) and 
DEPC water to a final volume of 25 µl. The PCR reactions were run in a thermo cycler 
machine (Biorad). 
Amplification conditions for the PCR reaction were 1 cycle of 3 minutes at 94°C for 
denaturation; 20-35 cycles for 1 minute at 94°C, 1 minute at 57°C and 1 minute at 72°C; 
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Table 2-1: PCR program set-up for Egr-1. 
PCR program for Egr-1was as follow: total of 35 cycles, 34 cycles from step 2 to 4.  
Steps Temperature Time 
1 94°C 3minutes 
2 94°C 1 minutes 
3 58°C 1 minutes 
4 72°C 1minute 
5 72°C 10 minutes 
 
 
Table 2-2: PCR program set-up for β-actin. 
 PCR program for β-actin was as follow: total 20 cycles, 19 cycles from step 2 to 4. 
Steps Temperature Time 
1 94°C 3 minutes 
2 94°C 1minute 
3 58°C 1 minute 
4 72°C 1 minute 
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2.9 Primers 
Egr-1 is the gene of interest and β-actin gene was used as a housekeeping gene for 
calibration; the primer sequence used was as follows: 
 
Table 2-3: Primer specification for Egr-1 and β-actin. 
Egr-1 (Reverse) CTCAACAGGGCAAGCATACG  
Egr-1 (Forward) TTTCCACAACAACAGGGAGAC  
β-actin (Forward) GTATGGAATCCTGTGGCATCC  
β-actin (Reverse) GACTCATCGTACTCCTGCTTG  
 
2.10 Gel electrophoresis for PCR 
Agarose gel electrophoresis was used to analyze the PCR reaction. PCR samples were 
resolved on 2% agarose gel prepared from 1X TAE buffer; and ethiduim bromide (10 
mg/ml) was added to the liquid agarose mixture before being casted. After loading the 
samples, the gel was left to run for 50 minutes at 90 volts. After electrophoresis, the gel 
was placed under Trans UV (Biorad) for imaging using Chemidoc XRS (Biorad).  
2.11 Densitometry 
 For densitometry, images were analysed using Quantity One Software (Biorad). The 
density of each amplified band for both the housekeeping gene (β-actin) and the gene of 
interest Egr-1 were measured using 1-D Image software Data Analysis (see Figure 3.13). 
All data were analyzed by calculating the average ratio, between the gene of interest Egr-
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1 and β-actin gene. Standard error was then provided for at least 6 samples of PCR for 
each of 3 biological experiments. Fold change was then calculated, using excel.  
Statistical analysis was done using Graph Pad Prism 7 software. Unpaired two-tailed t-tests 
were used to validate the fold change significance within each treatment. A probability 
level of p ≤ 0.05 was considered statistically significant. 
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Chapter 3  
RESULTS 
This chapter presents the experimental design and the results obtained for identifying the 
best timing for Egr-1 gene expression in NGF treated cells. Moreover, it assesses the 
statistical significance and the coefficient of variation using semi quantitative RT-PCR.  
3.1 Experimental design and analysis  
The experiment was designed to evaluate cellular response of NGF, by studying early 
gene transcriptional expression profile. This study was applied to PC12 cells, which is a 
clonal cell line derived from rat phenochromocytoma. For many years, PC12 cells have 
been used as an effective model for neuronal study. They share identical properties with 
neurons, as they have embryological origin from neuroblastic cells (Greene & Tischler, 
1976). The Egr-1 gene was selected because of its well-characterized response to NGF 
(Dijkmans et al., 2009). Data analysis was carried out on the expression level for Egr-1 
after treatment of NGF only (0.5 nM), or PMA only (80 nM), or a mixture of PD90780 
(100 µM) and NGF; or PD90780 (100 µM) and PMA. 
PD90780 is a non-peptide inhibitor that blocks NGF. It interacts with NGF and inhibit its 
binding to p75 (Spiegel et al., 1995). The expression profile for Egr-1 was normalized 
against the β-actin gene. PMA (Phorbol 12-myristate 13-acetate) has demonstrated the 
ability to induce the expression of Egr-1 in PC12 cells with peak expression after 1 hour 
before it decreases (Cheng et al., 1994).  
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PMA was chosen as a positive control to validate our results. The expression data were 
analyzed by semi quantitative polymerase chain reaction. Primers were designed as 
described in chapter 2. Agarose gel (2%) electrophoresis was performed to separate the 
PCR products. 
3.2 Egr-1 time course expression in NGF treated cells 
The effect of NGF on the expression of Egr-1 in PC12 cells was analyzed. PC12 cells were 
treated with NGF for 30, 45, 60, 90, and 180 minutes, and as a control. RNA was isolated 
from treated PC12 cells and the transcription level for Egr-1 and the β-actin genes were 
analyzed using RT- PCR.  
Results from semi quantitative PCR performed on cDNA from NGF treated cells show no 
significant increase in the expression of Egr-1 after 30 minutes (0.9 fold), or 45 minutes 
(0.9 fold). At 60 minutes there was minimal fold increase (1.1 fold) (Figure 3.1). The 
highest level of expression was noticed at 90 minutes (2.7 fold; *p value ≤ 0.05) (Figure 
3.2). Results from this study show that the expression for Egr-1 in NGF treated cells 
peaked at 90 minutes (2.7 fold) and declined at 180 minutes (1.0 fold) (Figure 3.2). 
PMA treated cells show changed expression of Egr-1 at 30 minutes (2.2 fold), 45 minutes 
(0.5 fold), 60 minutes (2.9 fold; *p value ≤ 0.05) (Figure 3.1), and the fold is decreased at 
90 minutes (2.6 fold) (Figure 3.2). Results from this study show that the expression of Egr-
1 in PMA treated cells peaked at 60 minutes and Egr-1 expression declined at 90 minutes. 
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Figure 3.1: Fold change for gene expression in NGF and PMA treated cells at 30, 45, 
and 60 minutes. 
(a) shows fold change for gene expression at 30 minutes for NGF treated 
cells (0.9 fold), and PMA treated cells (2.2 fold). (b) shows fold change for 
gene expression at 45 minutes for NGF treated cells (0.9 fold), and PMA 
treated cells (0.5 fold). (c) shows fold change for gene expression at 60 
minutes for NGF treated cells (1.1 fold), and PMA treated cells (2.9 fold; *p 
value ≤ 0.05). The fold change for NGF or PMA treated cells relative to the 
control cells are represented in this Graph. Unpaired two-tailed t-tests 
determined statistical significance between the control and PMA by Graph 














































































































Figure 3.2: Fold change for gene expression in NGF and PMA treated cells at 90, 
and 180 minutes. 
a) shows fold change for NGF treated cells at 90 minutes (2.7 fold; *p value 
≤ 0.05) and, PMA treated cells (2.6 fold) at 90 minutes. (b) shows fold 
change for NGF treated cells (1.0 fold) at 180 minutes. The fold change for 
NGF or PMA treated cells relative to control cells are represented in this 
graph. Unpaired two-tail t-tests determined statistical significance between 
the control and NGF at 90 minutes by Graph Pad Prism 7. Error bar 
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3.3 The effect of PD90780 on the expression of Egr-1 in NGF treated cells.  
Recent studies show that PD90780 is a potent NGF inhibitor (Sheffield et al., 2015). Based 
on these studies, PD90780 was chosen to analyze its effect on the expression of Egr-1 in 
NGF treated cells and validate its effect in cell signalling response. 
The results show Egr-1 expression fold change in NGF treated cells (0.9 fold), combination 
of NGF and PD90780 (1.2 fold), PMA and PD90780 (1.5 fold) and PMA alone (2.6 fold; 
*p value ≤ 0.05). Statistical significance for the control and PMA only, was determined by 
using unpaired two-tailed t-test by Graph Pad Prism 7. Error bars represent mean ± SEM 
(n-6). Results were considered statistically significant with p value ≤ 0.05. The fold change 
results for Egr-1 expression from cells treated with NGF alone didn’t show significant 
change through which the effect of the inhibitors can be assessed. 
  




Figure 3.3: Fold change for gene expression in NGF, PMA, or a mixture of NGF 
and PD90780 or PMA and PD90780 treated cells. 
Fold change of Egr-1 expression in NGF treated cells (0.9 fold),), or a 
mixture of NGF and PD (1.2 fold), or PMA treated cells (2.6 fold; *p value 
≤ 0.05), or PMA and PD) treated cells (1.5 fold; p* value ≤ 0.05. Statistical 
significance for the control and PMA only, and PMA and PD was 
determined by using unpaired two-tailed tests by Graph Pad Prism 7. Error 
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3.4 Coefficient of variation 
The coefficient of variation is a valuable statistical measure to compare different ranges of 
variability among various data. It is defined as the ratio of standard deviation to the mean 
value. The coefficient of variation for Egr-1 and β-actin gene expression between the six 
replicates for each treatment (PC12, NGF, PMA, and PD), at different timings (30, 45, 60, 
90 and 180 minutes) was calculated to compare the outcome for each experiment with 
different treatments applied. Table 3-1 through Table 3-6 show the detailed numerical data 
for different treatments at different timing, while Figure 3.4 through Figure 3.9 present 
comparisons between the coefficient of variation for Egr-1 and β-actin gene in the different 
experimental sets. Table 3-7 and Table 3-8 present a summary of the data presented in 
Table 3-1 through Table 3-6 in normalized forms. 
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Table 3-1: PCR products for β-actin gene, and the coefficient of variation results 
for PC12 cells.  
PCR products of β-actin amplified from 6 replicates of cDNA samples of PC12 cells for 
30, 45, 60, 90, 180 minute and PD experiments respectively. PCR products are separated 
on 2% agarose gel, visualized with ethiduim bromide after electrophoresis. Coefficient 
of variation is calculated by the ratio of standard deviation to the mean. 



































29108 15558 0.53 
180 minutes 
 
32865 9377 0.30 
PD experiment 
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Figure 3.4: The coefficient of variation graph for β-actin gene for PC12 cells. 
The coefficient of variation for 6 replicates of PC 12 cells for β-actin. 
While, the 180 minute experiment shows the minimal coefficient of 
variation (0.30), the 60 minute experiment shows the highest one (0.61). 
There is no significant difference between the coefficient of variation for 
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Table 3-2: PCR products for Egr-1 gene, and the coefficient of variation results 
for PC12 cells. 
PCR products of Egr-1 amplified from 6 replicates of cDNA samples of PC12 cells for 
30, 45, 60, 90, 180 minute and PD experiments respectively. PCR products are 
separated on 2% agarose gel, visualized with ethiduim bromide after electrophoresis. 
Coefficient of variation is calculated by the ratio of standard deviation to the mean. 



















14318 2658 0.18 
60 minutes 
 
14179 6857 0.48 
90 minutes 
 
21526 10624 0.49 
180 minutes 
 








































Figure 3.5: The coefficient of variation graph for Egr-1 gene for PC12 cells. 
The graph is representing the analysis for the coefficient of variation for 6 
replicates of PC 12 cells for Egr-1 gene. The highest coefficient variation 
is noted at 60, and 90 minute experiments. Whereas the 180 minute 
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Table 3-3: PCR products for Egr-1 gene, and the coefficient of variation results for 
NGF treated cells.  
PCR products of Egr-1 amplified from 6 replicates of cDNA samples of PC12 cells for 
30, 45, 60, 90, 180 minute and PD experiments respectively. PCR products are separated 
on 2% agarose gel, visualized with ethiduim bromide after electrophoresis. Coefficient 
of variation is calculated by the ratio of standard deviation to the mean. The 6th sample in 
30 minutes was analysed in different gel. 
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Figure 3.6: The coefficient of variation graph for Egr-1 gene in NGF treated cells. 
The graph represents the data for the coefficient of variation for 6 
replicates of NGF treated cells for Egr-1 gene. While, the 180 minute 
experiment shows the minimal coefficient of variation (0.05), the 60 
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Table 3-4: PCR products for β-actin gene, and the coefficient of variation results for 
NGF treated cells.  
PCR products of β-actin amplified from 6 replicates of cDNA samples of NGF treated 
cells for 30, 45, 60, 90, 180 minute and PD experiments respectively. PCR products are 
separated on 2% agarose gel, visualized with ethiduim bromide after electrophoresis. 
Coefficient of variation is calculated by the ratio of standard deviation to the mean. 






















24460 7259 0.29 
90 minutes 
 
16896 4033 0.23 
180 minutes 
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Figure 3.7: The coefficient of variation graph for β-actin gene in NGF treated cells. 
The coefficient of variation for 6 replicates of NGF treated cells for β-actin 
gene. The 45 minute experiment recorded the minimal coefficient of 
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Table 3-5: PCR products for Egr-1 gene, and the coefficient of variation results for 
PMA treated cells.  
PCR products of Egr-1 amplified from 6 replicates of cDNA samples of PMA treated 
cells for 30, 45, 60, 90, 180 minute and PD experiments respectively. PCR products are 
separated on 2% agarose gel, visualized with ethiduim bromide after electrophoresis. The 
coefficient of variation is calculated by the ratio of standard deviation to the mean. 
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90 minutes 
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Figure 3.8: The coefficient of variation graph for Egr-1 gene in PMA treated cells. 
The coefficient of variation of 6 replicates of PMA treated cells for Egr-1 
gene While, the 90 minute experiment shows the minimal coefficient of 
variation (0.06), the 60 minute experiment shows the highest one (0.33). 
The coefficients of variation for the 30 minute and the 45 minute 
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Table 3-6: PCR products for β-actin gene, and the coefficient of variation results 
for PMA treated cells.  
PCR products of β-actin amplified from 6 replicates of cDNA samples of PMA treated 
cells for 30, 45, 60, 90, 180 minute and PD experiments respectively. PCR products are 
separated on 2% agarose gel, visualized with ethiduim bromide after electrophoresis. 
Coefficient of variation is calculated by the ratio of standard deviation to the mean. 
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Figure 3.9: The coefficient of variation graph for β-actin gene in PMA treated cells. 
The coefficient of variations for 6 replicates of PMA treated cells for β-
actin gene. The 45 minute experiment recorded the minimal coefficient of 
variation (0.08). The 30 minute experiment shows the highest one (0.6). 
 
The results demonstrated that the coefficient of variation typically ranged from 0.4 to 0.6 
for the β-actin gene expression and from 0.2 to 0.4 for Egr-1 gene expression. As the gene 
expression is the ratio of Egr-1 to β-actin (see section 3.5), the coefficient of variation is 
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Table 3-7: Normalized data for β-actin gene in PC12 cells, NGF, PMA and PD 
treated cells.  
The table represents normalized data for β-actin gene for 6 replicates of PC12 cells, 
NGF, PMA and PD treated cells at 30, 45, 60, 90, 180 minute and PD experiments 
respectively.  













Average 13772 10933 16826 29108 32865 22755 
Standard 
deviation 8297 4389 10282 15558 9377 9342 
Coefficient of 
variation 0.6 0.4 0.61 0.53 0.3 0.41 
NGF 
Average 18593 14802 24460 16896 48619 12341 
Standard 
deviation 6080 1046 7259 4033 4713 3514 
Coefficient of 
variation 0.32 0.07 0.29 0.23 0.09 0.28 
PMA 
Average 9211 20921 13075 28034 N/A 24852 
Standard 
deviation 5413 1869 7289 15667 N/A 8811 
Coefficient of 
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Table 3-8: Normalized database for Egr-1 gene in pc12 cells, NGF and PMA, 
and PD treated cells.  
The table represents normalized data for Egr-1gene for 6 replicates of PC12 cells, 
NGF, PMA and PD treated cells at 30, 45, 60, 90, 180 minute and PD experiments 
respectively. 













Average 28836 14318 14179 21526 53576 10669 
Standard 
deviation 4745 2658 6857 10624 3864 1932 
Coefficient of 
variation 0.16 0.18 0.48 0.49 0.07 0.18 
NGF 
Average 42333 18610 24957 58203 84747 6287 
Standard 
deviation 8717 1192 9425 8716 4193 1338 
Coefficient of 
variation 0.2 0.06 0.37 0.14 0.05 0.21 
PMA 
Average 34715 16509 22069 63579 N/A 17443 
Standard 
deviation 10214 4241 7415 4074 N/A 4065 
Coefficient of 
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3.5 Gene expression analysis with semi quantitative RT-PCR technique 
Another goal in this thesis was to study cell-signalling response. Through this study, an 
inhibitory compound for NGF was tested by analyzing Egr-1 gene expression profile as a 
functional read out. Semi quantitative RT- PCR was applied to validate the results. Semi 
quantitative PCR technique is a standard tool in gene expression analysis. The great utility 
of this technique is a result of it being neither expensive nor difficult to perform. This 
method is semi quantitative as the amplification of the gene can be quantified to a certain 
degree. Differences in band intensity will also affect the interpretation of gene expression.  
 In this study, the experiments were repeated 3 times in 6 replicates. We noticed great 
variability in gene expression. For the first experiment, for NGF treated cells in the 90 
minute incubation period, the fold change was 2.7 fold; (*p value ≤ 0.05), the second 
experiment was (1.5 fold) and the third experiment was (0.9 fold). P value was ≥ 0.05 for 
the second and third experiment (Figure 3.10).  
For PMA treated cells in the 60 minute incubation period, the fold change for the first 
experiment was 2.9 fold; (*p value ≤ 0.05), the second experiment was (2.4 fold), and the 
third experiment was 2.7 fold; (*p value ≤ 0.05) (Figure 3.12). Statistical analysis was 
performed by using unpaired, two-tailed t-tests by Graph Pad Prism 7.  
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Figure 3.10: Three repeated experiments at 90 minutes for Egr-1 gene expression in 
NGF treated cells. 
Experiment 1 (2.7 fold; *p ≤ 0.05), experiment 2 (1.7 fold), and experiment 
3 (0.9 fold). Unpaired two-tailed t-tests determined statistical significance 
between the control and NGF for experiment 1 by Graph Pad Prism 7. Error 


















Figure 3.11: PCR bands for Egr-1 and β-actin gene. 
PCR bands for Egr-1 and β-actin gene for 6 replicates of NGF treated cells, 
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Figure 3.12: Three repeated experiments at 60 minutes for Egr-1 gene expression in   
PMA treated cells.  
Experiment 1 (2.9 fold; *p ≤ 0.05), experiment 2 (2.4 fold), and experiment 
3 (2.7 fold; *p value ≤ 0.05). Unpaired, two-tail t-tests determined statistical 
significance between the control and PMA for experiment 1 and experiment 
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Figure 3.13: The band analysis for gene expression. 
Band analysis for gene expression of 6 replicates for NGF treated cells, 
using densitometry analysed by 1-D Image Software Data Analysis. 
 
3.6 Statistical analysis 
Analysis of gene expression under different experimental conditions is important for 
informative functional analysis. In this study, semi quantitative RT-PCR was used for 
gene expression analysis. Statistical analyses were conducted using Graph Pad Prism 7. 
All experiments were repeated 3 times in 6 replicates, and statistical significance was 
determined using unpaired two-tail t-tests (p value ≤ 0.05).  
Having a positive fold change suggests that there is a differential expression. To 
determine whether this expression is statistically significant, the p value was calculated 
using unpaired two-tailed t-tests. 
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Table 3-9: Statistical results for Egr-1 gene expression in NGF treated cells. 
Egr-1 gene expression Time Standard Error P-Value 
30 minutes 0.32 
 
Ns 
45 minutes 0.03 Ns 
60 minutes 0.31 Ns 
90 minutes 0.57 P ≤ 0.05 







Chapter 4  
DISCUSSION 
This chapter discusses the results obtained from this study, and possible future work. The 
discussion begins by examining the importance of illustrating the time course expression 
level, and peak expression time for NGF treated cells. Moreover, it presents the 
advantages and disadvantages of common techniques to analyze gene expression profiles. 
Finally, it evaluates the application of the semi quantitative RT-PCR technique in using 
gene expression analysis as a functional read out.  
4.1 Identifying peak time expression for Egr-1 in NGF treated cells 
Several studies have been carried out to study the cellular response for NGF in PC12 cell 
line (Teng et al., 2006). As previously discussed, NGF stimulates the expression of the 
Egr-1 gene in PC12 cells. This study was conducted on the assumption that PC12 cells 
have a constant response to NGF. Moreover, it is assumed that the cells’ ability to 
express Egr-1 over time is constant. 
 These studies were not limited only to cellular phenotype, but also to transcriptional 
profiles (Kendall et al.,1994; Yan & Ziff, 1997). The studies of intracellular signalling 
pathways help determine the mechanisms by which all the neurotrophic factors carry out 
their biological response. 
For many decades, pain management has been a challenging task, and yet many patients 
still suffer from chronic pain. Small molecule inhibitors have been reported to inhibit 
NGF such as PD90780, ALE-0540 and Ro 08-275 (Sheffield el al., 2016). However, all 
Chapter 4: Discussion 
67 
of these molecules have not been tested in primary cell line yet to evaluate their 
effectiveness before the attempt of clinical trials.  
Many studies have shown that variability in NGF levels play a central role in chronic 
pain conditions such as arthritis and cystitis, some neuronal disorders such as 
Alzheimer’s and multiple sclerosis, in addition to some metabolic disorders such as 
diabetes (Acosta et al., 2013; Cattaneo & Calissano, 2012; Pittenger et al., 2003). We 
could pave the way for the development of new drugs for pain management and neuronal 
disorders by exploring the possibility of targeting NGF, and its signalling pathway, as 
well as by studying the effect of NGF inhibitors on the downstream signalling pathway. 
Moreover, studying the effect of the small inhibitory molecules can be of great help in 
pain management and in minimizing different side effects. Therefore, it is crucial to gain 
a better understanding of different signalling pathways in response to different stimuli.   
In this study, the aim was to determine gene expression of Egr-1 and to investigate the 
intricate results of signalling in NGF treated cells in comparison with cells treated with 
NGF together with NGF inhibitors. This study was based on the assumption that Egr-1 
gene basal expression is constant in the absence of any treatment.  
While signalling response and duration plays a fundamental role in assessing the results, 
it is crucial to identify the peak expression timing in NGF treated cells to analyze the 
response to these inhibitory molecules. Peak expression time for NGF treated cells using 
Egr-1 gene expression, as a functional read out analysis was studied. 
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Previous studies have analyzed gene expression at shorter time intervals, and have shown 
peak time expression for immediate early gene expression Egr-1 in NGF treated cells at 60 
minutes (D’Onofrio et al., 2011). In this study, the time course of the gene expression 
profile Egr-1 gene was extended to cover longer time intervals (30, 45, 60, 90, 180 
minutes), using semi quantitative RT-PCR, and the results were analyzed and compared. 
The results indicated that the expression for Egr-1 in NGF treated cells is a 2.7-fold 
increase at 90 minutes, while it is a 1.1-fold increase at 60 minutes. Our results at 60 
minutes are compatible with the outcomes from the previous studies found in literature 
(D’Onofrio et al., 2011). The present study also revealed that there is no increase in gene 
expression at 180 minutes. 
4.2 Strengths and limitations of semi quantitative technique RT-PCR in gene 
expression analysis in NGF treated cells 
For many decades, eradicating or decreasing the side effects during drug development was 
considered to be a major challenge for pharmaceutical drug development. In 1961, the 
discovery of mRNA opened the door for new hopes to discover progression of different 
diseases, new medications and a better understanding of the physiological mechanisms 
(Cobb, 2015).  
Over the past century, the evolution of molecular biology and advanced research in 
biochemistry has been used to identify the role of gene expression for different purposes. 
Gene expression analysis has three basic purposes: exploring different biological 
mechanisms, gene coding, and disease classification and subdivision. The study of the 
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disease subdivision is potent particularly in cancer research (Bittner et al., 2000; Golub et 
al., 1999).  
RNA is fundamental in studying protein regulation and gene expression profiles of multiple 
genes. Since the 1990’s, new methods have been developed to study the expression levels 
and sequencing of genetic material. From Gene Arrays to Next Generation sequencing 
(NGS) and transcriptome analysis, research studies were focused on amplification and 
quantification of RNA (Fryer et al., 2002). 
Biological pathway is the most reliable approach with regards to understanding the 
complexity of genetic networks, and their response to different stimuli (Cohen et al., 2000). 
Moreover, identifying different genes that can be expressed or inhibited can serve as a tool 
that can guide us to identify novel drug targets, as well as a sensitive diagnostic tools (Butte 
et al., 2000). 
While mRNA is a rich source of data, the interpretation of these data to get valuable 
information remains a big challenge. Until now, the drug screening is a big challenge, as it 
may be influenced by various factors including cost, time, ease of application, efficacy, and 
reliability. 
Despite having a wide variety of techniques, each one has its advantages and 
disadvantages. In general, the serial analysis of gene expression (SAGE) provides the best 
specificity with gene identity, but it is expensive and difficult to apply. With regards to the 
traditional Northern blot, it is considered to be the gold standard in quantifying RNA 
expression levels (Bhardwaj et al., 2012). However, this technique is capable of analyzing 
only one gene at a time. This repetitive analysis needs several blots, and on a large scale, 
Chapter 4: Discussion 
70 
this method is not only time consuming, but also extremely expensive. It uses extensive 
washing steps, and multiple film exposures to analyze the data. Furthermore, Northern 
blotting fails to detect low RNA abundance (Krumlauf, 1991).  
Semi quantitative RT-PCR is an outstanding method for gene expression analyses, 
especially when compared to Northern blot. It is able to analyze hundreds of samples and 
multiple targets, even those with small amounts of RNA. As a result, RT-PCR is classified 
among the most sensitive gene expression analysis techniques (Freeman et al.,1999). 
In this study, semi quantitative RT-PCR was applied to validate Egr-1 expression in NGF 
treated cells. The goal was to determine whether studying gene expression for NGF 
signalling is a valid and effective screening strategy to evaluate NGF inhibitors using 
semi quantitative RT-PCR.  Another aim of this study was to test different NGF 
inhibitory molecules by gene expression analysis using RT-PCR technique.  
Although RT-PCR is the most widely used technique for gene expression analysis, the 
reliability of the data produced from it can be affected by many factors, such as: primer 
optimization, normalization of gene expression, gel imaging resolution, and variability of 
the housekeeping gene. In order to standardize the PCR results, a housekeeping gene is 
usually employed to ensure consistent gene expression regardless of any treatment. In 
these experiments, a housekeeping gene is defined as a gene that does not vary in 
expression (i.e. has constant expression) regardless of all status, such as differentiation or 
manipulations. This study was based on six replicates for each treatment as a way to 
minimize the variation.  
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Statistical analyses were conducted for all the experiments to validate the data obtained. 
The standard error was calculated for different treatments at different time points. There 
were no significant differences between the treatment groups due to high variability within 
same groups of samples with different treatments (see Table 3-1,Table 3-2,Table 3-
3,Table 3-4,Table 3-5, and Table 3-6). 
To pinpoint the cause of variability, the coefficient of variation between the six replicates 
for each treatment at different timings were calculated. The coefficient of variation is a 
valuable statistical measure to compare different ranges of variability among various data. 
It is represented by the ratio of the standard deviation to the value of the mean, the higher 
the coefficient of variation the higher the dispersion.  
 The coefficient of variation for the PC12 cells for the β-actin gene (housekeeping gene), 
for the 30, 45, 60, 90, 180 minute and PD experiments, are 0.6, 0.4, 0.61, 0.53, 0.28, and 
0.4 respectively (see Figure 3.4). The coefficient of variation for PC 12 cells in Egr-1 are 
0.16, 0.18, 0.5, 0.5, 0.07 and 0.18 in 30, 45, 60, 90, 180 minute and PD experiments 
respectively (see Figure 3.5). 
The coefficient of variation for Egr-1 data in NGF treated cells take the values 0.2, 0.06, 
0.4, 0.14, 0.05 and 0.2 in the 30, 45, 60, 90, 180 minute and PD experiments, respectively 
(see Figure 3.6). The coefficient of variation for the NGF treated cells for the β-actin gene 
take the values 0.32, 0.32, 0.3, 0.24, 0.09, and 0.28 in the 30, 45, 60, 90, 180 minute and 
PD experiments, respectively (see Figure 3.7).  
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The coefficient of variation for PMA treated cells for Egr-1, it takes the values 0.3, 0.26, 
0.33, 0.64 and 0.21 in the 0, 45, 60, 90 minute and PD experiments respectively, and for β-
actin takes the values 0.5, 0.09, 0.55, 0.55 and 0.4, (see Figure 3.8 and Figure 3.9).  
It is very important to consider the efficacy of amplification to ensure that the results 
collected are accurate and reliable. Moreover, studies have suggested that the most 
recommended housekeeping gene is the one that shows the lowest coefficient of variation 
in its expression. While the housekeeping gene role depends on keeping consistent gene 
expression regardless of any treatment, the coefficient of variation typically varied 
between 0.4 to 0.6 for the β-actin gene, and for Egr-1 it varied between 0.2 to 0.4.  
To date, most studies determining β-actin signals as an internal control for gene 
expression analysis rely on the assumption that the expression level in the cells remains 
the same. However, there is evidence that shows that this is an unreliable assumption, 
with significant alterations in the expression for the β-actin gene in some studies 
(Waxman & Wurmbach, 2007). Unfortunately, a considerable reference gene for neural 
differentiation studies have not been proven yet. 
Taking into consideration the fact that the housekeeping gene has to be constant, it was 
noted that the coefficient of variation fell within a wide range for the β-actin gene. 
Therefore, calculating the ratio of Egr-1 to β-actin to assess the fold change will not 
provide accurate results.  
There are multiple advantages for using RT-PCR for gene expression analysis. It is 
simple to apply, inexpensive, and produces rapid results. Additionally, it is a sensitive 
technique that allows small amounts of RNA to be amplified to billions of copies, 
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(Templeton, 1992). However, it has several limitations (Smith & Osborn, 2009). One of 
these limitations includes the use of agarose gel for analysis. Using gels may not be able 
to resolve variability between samples, causing variability in bands intensities, and 
imprecise results (Figure 3.11). As the quantification method is based on evaluating the 
band intensity from gel electrophoresis, a difference in the intensity of one band may be 
interpreted differently leading to imprecise results. 
Gene expression data obtained from PCR analysis is a complex procedure and several 
steps are required. Data collected from RT-PCR is at the end point of the reaction, which 
may not be precise. Moreover, these data are interpreted by band visualization in the gel 
cast under UV light. Agarose gel is used for the detection of the end point of PCR 
reactions (the plateau phase). The plateau phase detects gene expression results once the 
reaction is stopped. Moreover, the high variability for the coefficient of variation for the 
housekeeping gene has a significant role in the productivity of imprecise results. 
Although the data showed a fold increase of 1.1 at 60 minutes for NGF treated cells, 
which is consistent with other published reports (D’Onofrio et al., 2011), due to the 
standard error variability, and the high coefficient of variation, these results obtained by 
semi quantitative PCR technique cannot be considered significant. 
In this study, the results showed positive fold change throughout the time course, which 
suggests that the Egr-1 gene is expressed and that the signalling pathway is activated. 
Although, the data obtained contains plenty of valuable information, it is usually flawed 
with variability and consistency issues. Unfortunately, data analysis for gene expression 
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cannot depend only on fold change results, as there are many biological variables that can 
be significant and need to be studied.  
By comparing the experimental results for NGF treated cells in 90 minutes (Figure 3.10), 
we noticed variability through each experiment, despite following the protocol very 
closely. In the first experiment, the fold change was 2.7 fold, the second experiment was 
1.7 fold and the third experiment was 0.9 fold. Statistical analysis showed statistical 
significance for the first experiment and did not show significant difference from non-
treated cells for the second and third experiment. 
By comparing the experimental results in PMA treated cells at 60 minutes (Figure 3.12), it 
was also noticed variability in the fold change, experiment (1) 2.9 fold, experiment (2) 2.4 
fold, and experiment (3) 2.6 fold. Experiments 1 and 3 are statistically significant. The 
statistical analysis did not show significant difference compared to non-treated cells for 
experiment 2.  
Previous studies have shown peaked fold change for Egr-1 expression in NGF treated cells 
at 1.4 fold at 60 minutes (D’Onofrio et al., 2011). In this study, the Egr-1 expression 
increased to 2.7 fold and 1.7 fold at 90 minutes. However, due to the standard error 
variability, this data was also not significantly different from non-treated cells. 
During this work, the effect of PD90780, a potent NGF inhibitor, was studied on cellular 
expression of Egr-1. This inhibitor has been chosen to test its effect on cellular response, 
which, in turn, will give a better understanding of its effect as an inhibitor (Spiegel et al., 
1995). Statistical significance was shown between the control and PMA treated cells only. 
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Moreover, the results did not show the fold change in NGF treated cells by which PD90780 
inhibitory effects can be validated.  
In conclusion, and despite the variability of the results we obtained regarding the fold 
change in Egr-1 gene expression, a trend has been observed showing an increase in the 
expression levels following treatment with NGF. This is corroborated with previous 
publications showing similar results.  
Whereas semi quantitative RT-PCR method can be used for initial studies, it has to be 
substantiated with other more accurate methods for gene expression analysis (e.g., real time 
quantitative PCR). Real time quantitative PCR monitors the DNA amplification during the 
exponential growth phase of PCR. Therefore, data can be collected at the exponential 
growth phase, which results in more sensitive and precise results. Although real time 
quantitative PCR technique allows for a dynamic monitoring of the reaction during the 
exponential phase, and thus analyzes the relative expression of different genes, real time 
PCR is an expensive technique to be used for drug screening.  
While semi quantitative RT-PCR technique, as used in this study, is a simple and 
inexpensive method for gene expression analysis, it may not be the most suitable method 
for examining small differences in gene expression analysis due to variability and 
inaccuracy in the results. 
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CONCLUDING REMARKS AND FUTURE WORK 
Gene expression analysis is a powerful technique to study the signalling pathway, and 
examine different responses. In this study, a semi quantitative technique has been used to 
validate the results. NGF expression was obtained throughout the time course and peak 
expression shown at 90 minutes. However, the results indicate a need for a more robust and 
reproducible method for gene expression analysis in NGF treated cells. It is suggested to 
apply the same study using real time quantitative PCR technique, as it detects amplification 
during the reaction precisely in the exponential phase (the optimal point for data analysis). 
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